Indications |
Oral Adjunct in cortical myoclonus Adult: 7.2 g daily in 2-3 divided doses, increased by 4.8 g/day every 3-4 days. Max dose: 20 g daily.
Oral As a cognitive enhancer in cerebrocortical insufficiency Adult: 2.4 g daily, given as 2-3 divided doses. Up to 4.8 g daily may be used in severe cases.
Parenteral As a cognitive enhancer in cerebrocortical insufficiency Adult: 1-2 g tid via IV/IM admin. Special Populations: Patients with mild to moderate renal impairment: CrCl: 40-60 mL/min: ½ the usual dose; 20-40 mL/min: Quarter of the usual dose. |
||||||||||||||||||||
Contraindications |
Hepatic and severe renal impairment. Cerebral haemorrhage. Pregnancy and lactation. | ||||||||||||||||||||
Warnings / Precautions |
Avoid abrupt withdrawal. Impaired renal function. Cardiac disorders. Haemostatic disorders. Patients who have recently undergone major surgery. Elderly. | ||||||||||||||||||||
Adverse Reactions |
Hyperkinesia, nervousness, depression, diarrhoea, rashes. CNS stimulation, sleep disturbances, dizziness, excitement, insomnia, somnolence, wt gain. | ||||||||||||||||||||
Drug Interactions |
May increase prothrombin time in patients who are on warfarin. See Below for More piracetam Drug Interactions |
||||||||||||||||||||
Mechanism of Actions |
Piracetam protects the cerebral cortex against hypoxia. It also inhibits platelet aggregation and reduces blood viscosity. | ||||||||||||||||||||
Administration |
Soln: May be taken with or without food. (Take w/ a glass of water or soft drink after taking the undiluted soln to mask bitter taste. ) |
||||||||||||||||||||
ATC Classification |
N06BX03 - piracetam ; Belongs to the class of other psychostimulants and nootropics. | ||||||||||||||||||||
Available As |
|
Piracetam
Post Review about Piracetam Click here to cancel reply.
Piracetam Containing Brands
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.